What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

VEGF Notch Signaling: Mechanisms and Roles in Angiogenesis

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to VEGF and Notch Signaling

Blood vessel formation is one of the most tightly regulated morphogenetic processes in vertebrates. The vascular system must assemble a hierarchical network of arteries, capillaries, and veins, and it must do so with remarkable precision—too few vessels starves tissue, too many produces chaotic, non-functional plexuses. Two signaling pathways dominate this process: vascular endothelial growth factor (VEGF) signaling, which provides the primary pro-angiogenic drive, and Notch signaling, which acts as a braking mechanism that refines and patterns the VEGF response. These two pathways do not operate independently; they form an integrated feedback circuit that determines which endothelial cells sprout, which follow, and which form the lumen of a new vessel.

Understanding this interplay is essential not only for basic vascular biology but also for rational design of anti-angiogenic therapies. Over 30 anti-VEGF drugs are in clinical use or trials, and Notch pathway modulators are following close behind. This article dissects the molecular mechanisms of both pathways, explains how they communicate, and explores their combined roles in development, disease, and therapy.

Overview of VEGF Signaling

VEGF (vascular endothelial growth factor) is a secreted dimeric glycoprotein that acts as the master regulator of angiogenesis. The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF), with VEGF-A being the most extensively studied and the dominant driver of blood vessel growth. VEGF-A exists in multiple splice isoforms (VEGF121, VEGF165, VEGF189, VEGF206 in humans) that differ in their heparin-binding affinity and therefore in their diffusion range through the extracellular matrix. VEGF165 is the most abundant and biologically active isoform.

VEGF-A signals through two main receptor tyrosine kinases: VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1). VEGFR2 is the principal signaling receptor that mediates the pro-angiogenic effects of VEGF—proliferation, migration, survival, and vascular permeability. VEGFR1 has a higher affinity for VEGF-A but weaker kinase activity, and it functions largely as a decoy receptor that sequesters VEGF and restricts its access to VEGFR2. A third receptor, VEGFR3 (Flt-4), binds VEGF-C and VEGF-D and is critical for lymphatic development.

Overview of Notch Signaling

Notch signaling is an evolutionarily ancient, contact-dependent cell–cell communication system. Unlike VEGF signaling, which uses secreted ligands and receptor tyrosine kinases, Notch signaling requires direct physical contact between a signal-sending cell and a signal-receiving cell. The Notch receptor is a single-pass transmembrane protein that, upon engagement with a transmembrane ligand on an adjacent cell, undergoes a series of proteolytic cleavages that release its intracellular domain. This domain then translocates to the nucleus and acts as a transcriptional co-activator.

In mammals, there are four Notch receptors (Notch1–4) and five canonical ligands: Delta-like 1 (Dll1), Delta-like 3 (Dll3), Delta-like 4 (Dll4), Jagged1, and Jagged2. In the vascular system, Notch1 and Notch4 are the predominant receptors on endothelial cells, while Dll4 and Jagged1 are the key ligands. The Notch Signaling Pathway is detailed in its own reference, but the vascular-specific aspects are covered here.

The VEGF Signaling Pathway

VEGF Ligands and Receptors

VEGF-A is produced by many cell types, including hypoxic cells, tumor cells, and macrophages. Hypoxia is the primary physiological stimulus: low oxygen stabilizes hypoxia-inducible factor 1α (HIF-1α), which then drives transcription of the VEGF-A gene. Once secreted, VEGF-A binds to heparan sulfate proteoglycans on the cell surface and extracellular matrix, creating a local gradient that guides endothelial cell migration.

VEGFR2 is the dominant signaling receptor on endothelial cells. It is a class V receptor tyrosine kinase with seven immunoglobulin-like domains in its extracellular region, a single transmembrane domain, and an intracellular split kinase domain. Ligand binding induces receptor dimerization and autophosphorylation at specific tyrosine residues. Key phosphorylation sites include:

Tyr1175 (human numbering): binds the adaptor protein SHC, leading to activation of the MAPK/ERK pathway, and also binds PLCγ, leading to activation of PKC and the Raf-MEK-ERK cascade.
Tyr951: binds the T-cell-specific adaptor (TSAd), promoting endothelial cell migration via Src kinase.
Tyr1214: activates the CDC42 and p38 MAPK pathways, contributing to actin reorganization.

VEGFR1, in contrast, has a much higher affinity for VEGF-A (Kd ≈ 2–10 pM versus ≈ 75–760 pM for VEGFR2) but very weak kinase activity. It acts primarily as a negative regulator by sequestering VEGF-A and by forming inactive VEGFR1/VEGFR2 heterodimers. However, VEGFR1 signaling does have context-dependent roles in monocyte/macrophage migration and in pathological angiogenesis.

Downstream Intracellular Signaling

VEGFR2 activation triggers several downstream cascades that coordinate the angiogenic response:

MAPK/ERK pathway: Phosphorylated Tyr1175 recruits SHC and GRB2, which activate the Ras-Raf-MEK-ERK cascade. ERK translocates to the nucleus and phosphorylates transcription factors such as ELK1 and c-Myc, driving expression of genes involved in proliferation and survival.

PI3K/AKT pathway: Tyr1175 also recruits the p85 regulatory subunit of PI3K, generating PIP3 at the membrane. PIP3 recruits AKT, which is phosphorylated by PDK1 (at Thr308) and mTORC2 (at Ser473). Active AKT promotes endothelial cell survival by phosphorylating and inactivating pro-apoptotic proteins such as BAD and FOXO transcription factors, and it stimulates nitric oxide production via eNOS activation.

PLCγ/PKC pathway: PLCγ binds to phosphorylated Tyr1175 and hydrolyzes PIP2 to generate IP3 and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, and DAG activates protein kinase C (PKC). PKC, particularly PKCβ, activates the Raf-MEK-ERK cascade and also promotes vascular permeability.

FAK and paxillin signaling: VEGF promotes focal adhesion turnover through Src-mediated phosphorylation of focal adhesion kinase (FAK), enabling endothelial cell migration.

The net result of these cascades is a coordinated program of endothelial cell proliferation, migration, survival, and lumen formation. However, the response is not uniform across all endothelial cells—and this is where Notch signaling becomes critical.

The Notch Signaling Pathway

Notch Receptors and Ligands

Notch receptors are synthesized as single precursor proteins that are cleaved by a furin-like convertase in the trans-Golgi network (S1 cleavage). This produces a heterodimer consisting of a large extracellular domain non-covalently associated with a transmembrane/intracellular fragment. The extracellular domain contains 29–36 epidermal growth factor (EGF)-like repeats, which mediate ligand binding, followed by a negative regulatory region (NRR) that keeps the receptor inactive in the absence of ligand.

The ligands Dll4 and Jagged1 are also transmembrane proteins with EGF-like repeats and a Delta/Serrate/Lag-2 (DSL) domain required for receptor binding. Dll4 is expressed specifically in arterial endothelial cells and is the dominant Notch ligand in sprouting angiogenesis. Jagged1 is more broadly expressed and, in some contexts, acts as an antagonist of Dll4-mediated Notch signaling because it is a weaker activator and can compete for receptor binding.

γ-Secretase-Mediated Cleavage and CSL Transcription

When a Notch ligand on a signal-sending cell engages a Notch receptor on a signal-receiving cell, it initiates a sequence of proteolytic events:

S2 cleavage: Ligand binding induces a conformational change in the NRR, exposing a site in the extracellular juxtamembrane region that is cleaved by ADAM10 (a disintegrin and metalloprotease 10) or ADAM17 (TACE). This removes the extracellular domain, leaving a membrane-tethered intermediate called NEXT (Notch extracellular truncation).

S3 cleavage: The NEXT fragment is then cleaved within its transmembrane domain by the γ-secretase complex, a multi-subunit protease composed of presenilin 1 or 2, nicastrin, APH-1, and PEN-2. This releases the Notch intracellular domain (NICD) into the cytoplasm.

Nuclear translocation and transcription: NICD translocates to the nucleus, where it binds the CSL transcription factor (CBF1/RBP-Jκ in mammals, Suppressor of Hairless in Drosophila, LAG-1 in C. elegans). In the absence of NICD, CSL acts as a transcriptional repressor by recruiting co-repressors such as SMRT/NCoR. NICD binding displaces these co-repressors and recruits the co-activator Mastermind-like (MAML), forming a ternary NICD-CSL-MAML complex that activates transcription of Notch target genes.

Key Notch target genes in endothelial cells include the basic helix-loop-helix (bHLH) transcriptional repressors HEY1, HEY2, and HRT3/HESR, as well as NRARP (Notch-regulated ankyrin repeat protein). HEY proteins repress the expression of VEGFR2 and other pro-angiogenic genes, providing the molecular link between Notch activation and reduced VEGF responsiveness.

The Notch Delta Signaling article provides additional detail on ligand-receptor interactions, and the broader Notch Signaling Pathway reference covers the core mechanism.

Cross-Talk Between VEGF and Notch Signaling

VEGF-Induced Dll4 Upregulation

The connection between VEGF and Notch signaling is bidirectional and forms a negative feedback loop. The initiating event in sprouting angiogenesis is VEGF-A binding to VEGFR2 on endothelial cells. One of the immediate transcriptional responses is upregulation of Dll4. The VEGF-VEGFR2 signal activates the MAPK/ERK pathway, which drives Dll4 transcription via the transcription factor FOXC1 and other ERK-responsive elements in the Dll4 promoter. Hypoxia also directly upregulates Dll4 via HIF-1α binding to hypoxia response elements.

The functional consequence is that VEGF-stimulated endothelial cells begin to express Dll4 on their surface. Because Dll4 is a transmembrane ligand, it can only signal to adjacent cells that are in direct physical contact. This creates a spatial pattern: the cell receiving the strongest VEGF signal expresses the most Dll4 and signals to its neighbors.

Notch-Mediated Suppression of VEGFR2

When Dll4 on a signal-sending endothelial cell engages Notch1 on a neighboring cell, the receiving cell undergoes γ-secretase-mediated cleavage and releases NICD. NICD-CSL-MAML then drives expression of HEY1 and HEY2, which bind to the VEGFR2 promoter and repress its transcription. The receiving cell also shows reduced expression of VEGFR1, NRARP, and other pro-angiogenic genes, and increased expression of the Notch target gene NRARP which further modulates the pathway.

The result is a dramatic reduction in the receiving cell's ability to respond to VEGF. This cell becomes less migratory and less proliferative, and instead adopts a "stalk cell" phenotype—a cell that trails behind the leading tip cell and proliferates to elongate the sprout. The tip cell, which has high VEGF signaling and high Dll4, maintains its responsiveness and extends filopodia to sense the VEGF gradient.

This lateral inhibition mechanism is conceptually analogous to the Notch Signaling in Neurogenesis process, where Notch signaling between adjacent progenitor cells forces them into different fates. In both systems, Notch amplifies small initial differences in signaling strength into discrete, all-or-nothing cell fate decisions.

Role in Angiogenesis and Vascular Patterning

Tip and Stalk Cell Specification

Sprouting angiogenesis proceeds through a stereotyped sequence:

VEGF gradient detection: A VEGF-A gradient, established by hypoxia in the avascular tissue, is detected by endothelial cells in the existing vessel wall.

Tip cell selection: The endothelial cell experiencing the highest VEGF concentration upregulates Dll4 and extends numerous filopodia, becoming the tip cell. This cell is highly migratory but does not proliferate extensively.

Stalk cell recruitment: The tip cell signals via Dll4-Notch to adjacent endothelial cells, suppressing their VEGFR2 expression and converting them into stalk cells. Stalk cells proliferate and form the vascular lumen behind the advancing tip cell.

Sprout elongation and anastomosis: The stalk cells elongate the sprout, and the tip cell eventually contacts another sprout or vessel to form a new connection. Upon anastomosis, the lumen connects and blood flow begins.

Pruning and maturation: Once perfusion is established, the VEGF gradient collapses, Dll4 expression falls, and the vessel stabilizes through recruitment of pericytes and smooth muscle cells.

The tip/stalk cell decision is not irreversible. If a tip cell loses access to VEGF or if its Dll4 signaling is blocked, it can revert to a stalk cell phenotype, and a neighboring stalk cell can take over as the new tip cell. This plasticity allows the sprout to adapt to changing environmental conditions.

Arterial-Venous Differentiation

The VEGF-Notch axis also plays a critical role in specifying arterial versus venous identity. During development, VEGF signaling promotes arterial fate: VEGF-A induces expression of Dll4 and Notch1 in arterial endothelial cells, and Notch signaling in turn upregulates arterial markers such as EphrinB2 and suppresses venous markers such as EphB4. Mice lacking Dll4, Notch1, or RBP-Jκ in endothelial cells show severe defects in arterial specification, with arteries acquiring venous characteristics.

This arterial-venous specification is essential for establishing the proper direction of blood flow. The Notch pathway also interacts with other signaling systems, including the Wnt Signaling Pathway, to coordinate vascular development with surrounding tissue patterning.

Experimental Methods to Study VEGF-Notch Signaling

Genetic Models in Mice and Zebrafish

The most powerful approach to studying VEGF-Notch signaling has been genetic manipulation in model organisms.

Mouse knockouts: Global knockout of VEGF-A, VEGFR2, Dll4, or Notch1 is embryonic lethal due to severe vascular defects. Dll4 heterozygous mice (Dll4⁺/⁻) survive but show striking vascular abnormalities, including increased vessel branching and density, demonstrating that Dll4 gene dosage is critical. Endothelial-specific knockouts using Cre-loxP technology (e.g., Tie2-Cre or VE-cadherin-Cre) allow temporal and spatial control of gene deletion.

Zebrafish: The zebrafish is particularly useful because its external development and optical clarity allow direct visualization of vascular sprouting. The fli1:EGFP transgenic line labels all endothelial cells with green fluorescent protein, enabling live imaging of tip cell selection and sprout formation. Morpholino knockdown or CRISPR-mediated mutation of dll4, notch1b, or vegfaa produces characteristic phenotypes: excessive branching (Dll4 loss) or reduced sprouting (Notch gain-of-function).

Inducible systems: To study the dynamics of the feedback loop, researchers use inducible Cre systems (e.g., tamoxifen-inducible CreERT2) or drug-inducible expression systems. These allow acute perturbation of the pathway at defined developmental stages.

In Vitro Endothelial Cell Assays

Several in vitro assays are standard for dissecting the molecular mechanisms:

Tube formation assay: Endothelial cells (typically human umbilical vein endothelial cells, HUVECs) are plated on Matrigel, a basement membrane matrix. Within 4–12 hours, cells align and form capillary-like tube networks. Adding VEGF promotes tube formation, while Dll4-Fc (a soluble Dll4 that blocks Notch signaling) or γ-secretase inhibitors (e.g., DAPT at 10–50 µM) increases branching and reduces lumen diameter.

Sprouting assay: Endothelial cell spheroids are embedded in a collagen or fibrin gel and stimulated with VEGF. Sprouts emerge over 24–48 hours, and the number and length of sprouts can be quantified. This assay recapitulates the tip/stalk cell decision and is sensitive to Notch pathway modulation.

Co-culture assays: To study cell-cell signaling directly, one population of cells (e.g., Dll4-expressing cells) is co-cultured with reporter cells expressing a Notch reporter construct (e.g., a CSL-driven luciferase or GFP reporter). This allows quantitative measurement of Notch activation in response to defined ligand presentation.

Signaling pathway analysis: Western blotting for phosphorylated VEGFR2 (pY1175), cleaved NICD, and downstream effectors (pERK, pAKT) provides biochemical confirmation of pathway activity. Quantitative RT-PCR for Dll4, HEY1, HEY2, and VEGFR2 mRNA levels is used to assess transcriptional responses.

Clinical Relevance and Therapeutic Targeting

Anti-Angiogenic Therapy

The VEGF-Notch axis is a major therapeutic target in diseases characterized by pathological angiogenesis, most notably cancer and neovascular age-related macular degeneration (AMD).

Anti-VEGF therapy: Bevacizumab (Avastin), a humanized monoclonal antibody against VEGF-A, was the first anti-angiogenic agent approved for cancer. It is used in combination with chemotherapy for metastatic colorectal cancer, non-small cell lung cancer, and other malignancies. Ranibizumab (Lucentis) and aflibercept (Eylea) are anti-VEGF agents used as intravitreal injections for wet AMD and diabetic macular edema. These drugs reduce vascular permeability and suppress new vessel growth, but they have limitations: many tumors develop resistance, and chronic anti-VEGF therapy can cause cardiovascular side effects.

Resistance mechanisms: Tumors often upregulate alternative angiogenic factors (e.g., FGF, PDGF, Angiopoietin-2) or become more invasive to escape the hypoxic environment created by vessel regression. Importantly, anti-VEGF therapy can paradoxically increase Dll4 expression in some contexts, activating Notch signaling and promoting a more quiescent, normalized vasculature that is actually more efficient at delivering chemotherapy.

Notch Inhibitors in Clinical Trials

Because Dll4-Notch signaling limits vessel branching, inhibiting Notch signaling was initially proposed as a strategy to produce more extensive, albeit abnormal, vessel growth. However, the reality is more complex.

γ-Secretase inhibitors (GSIs): Drugs such as DAPT, RO4929097, and MK-0752 block the S3 cleavage of Notch receptors, preventing NICD release. In preclinical models, GSIs increase vascular density but produce non-functional, leaky vessels with poor perfusion. This paradoxically can improve chemotherapy delivery by normalizing the tumor vasculature. Several GSIs have entered clinical trials for cancer, but their utility is limited by on-target gastrointestinal toxicity (due to Notch's role in intestinal goblet cell differentiation) and by the fact that they inhibit all Notch receptors, not just those involved in angiogenesis.

Anti-Dll4 antibodies: More selective approaches target Dll4 specifically. The anti-Dll4 monoclonal antibody (e.g., demcizumab) blocks Dll4-mediated Notch signaling in endothelial cells. Preclinical studies showed that anti-Dll4 treatment causes excessive, non-productive angiogenesis with poor perfusion, and it inhibits tumor growth in some models. However, chronic Dll4 blockade causes vascular neoplasms in the liver (hepatic vascular tumors) in animal models, raising safety concerns. Clinical trials of demcizumab in combination with chemotherapy for pancreatic cancer and non-small cell lung cancer have been conducted, though results have been mixed.

Notch1-specific inhibitors: More recent efforts focus on selective inhibition of Notch1, which is the primary receptor for Dll4 in angiogenesis. Antibodies that block the Notch1 NRR (e.g., brontictuzumab) prevent ligand-induced cleavage without affecting Notch2, Notch3, or Notch4. These agents may have a better therapeutic window than pan-Notch inhibitors.

The Notch Signaling in Cancer reference provides additional context on Notch pathway dysregulation in malignancy.

Common Pitfalls and Misconceptions

Misinterpreting the Feedback Loop

A frequent error is describing the VEGF-Notch interaction as a simple linear pathway: "VEGF activates Notch, which inhibits VEGF." While this captures the essence, it misses the spatial and temporal dynamics. The loop operates at the level of individual cells in a tissue: VEGF activates Dll4 in one cell, which then inhibits VEGF responsiveness in a neighboring cell. This is a lateral inhibition circuit, not a simple intracellular feedback loop. Students should also note that Notch does not directly inhibit VEGF signaling in the same cell—it suppresses VEGFR2 expression in the receiving cell, making that cell less sensitive to VEGF.

Another misconception is that Notch signaling is uniformly inhibitory. In reality, Notch can promote or inhibit angiogenesis depending on context. For example, Notch signaling in stalk cells promotes proliferation and lumen formation, while in tip cells it suppresses the tip phenotype. Notch also promotes arterial fate and vessel maturation. The outcome depends on which ligands and receptors are expressed, the timing of activation, and the cellular context.

Overlooking Ligand Specificity

Students often treat "Notch signaling" as a single entity, but ligand identity matters enormously. Dll4 and Jagged1 have opposing effects in some contexts. Jagged1 is a weaker Notch activator than Dll4, and in endothelial cells, Jagged1 can actually antagonize Dll4-mediated Notch signaling by competing for Notch1 binding. This means that the ratio of Dll4 to Jagged1 determines the net Notch signal strength. In tumors, Jagged1 is often upregulated, which may reduce Notch signaling in endothelial cells and promote more vigorous sprouting.

Similarly, Notch receptor identity matters. Notch1 is the primary receptor for Dll4 in vascular development, but Notch4 also contributes. Notch3 is expressed in pericytes and smooth muscle cells, where it regulates vessel maturation. Inhibitors that target all Notch receptors will have different effects than those that target Notch1 alone.

Ignoring Context-Dependent Effects

The VEGF-Notch axis behaves differently in development, adult homeostasis, and disease. In development, the system is highly plastic and essential for proper patterning. In the adult, VEGF-Notch signaling is largely quiescent except during wound healing, the female reproductive cycle, and pathological conditions. In tumors, the signaling dynamics are distorted by chronic hypoxia, genetic mutations, and the presence of multiple cell types. Conclusions drawn from developmental studies do not always translate directly to cancer biology.

Another common error is assuming that the tip/stalk cell decision is binary and irreversible. In reality, endothelial cells continuously sample their environment, and the tip/stalk phenotype is dynamically regulated. Cells can switch between states, and the "tip cell" is not a fixed lineage but a transient behavioral state.

Summary and Key Takeaways

The VEGF-Notch signaling axis is a master regulator of angiogenesis, coordinating the behavior of individual endothelial cells into a coherent vascular network. VEGF provides the driving force for sprouting, while Notch provides the spatial refinement that ensures efficient, functional vessel formation.

Frequently Asked Questions

What is the relationship between VEGF and Notch signaling?

VEGF and Notch signaling form a negative feedback loop that controls endothelial cell behavior during angiogenesis. VEGF activates VEGFR2, which upregulates expression of the Notch ligand Dll4. Dll4 then activates Notch receptors on adjacent endothelial cells, which suppresses their VEGFR2 expression and reduces their responsiveness to VEGF. This creates a lateral inhibition circuit that forces neighboring cells into different fates: one becomes a leading tip cell (high VEGF signaling, high Dll4) and the others become trailing stalk cells (high Notch signaling, low VEGFR2).

How does VEGF-Notch signaling regulate angiogenesis?

The pathway regulates the three key steps of sprouting angiogenesis: tip cell selection, stalk cell elongation, and vessel patterning. VEGF selects the tip cell and promotes its migration. Dll4-Notch signaling converts neighboring cells into stalk cells that proliferate and form the vascular lumen. The balance between VEGF and Notch signaling determines vessel density, branching pattern, and the size of the vascular network. Too much VEGF relative to Notch produces excessive, disorganized branching; too much Notch suppresses sprouting entirely.

What is the role of Dll4 in VEGF-Notch signaling?

Dll4 is the critical Notch ligand in vascular development. It is upregulated by VEGF signaling and is expressed specifically in arterial endothelial cells and tip cells. Dll4 acts as the signal that transmits the "tip cell" instruction to neighboring cells, activating Notch1 and suppressing their VEGFR2 expression. Dll4 gene dosage is critical: Dll4 haploinsufficiency (one functional copy instead of two) causes excessive vessel branching and embryonic lethality in mice, demonstrating that precise levels of Dll4 are required for normal vascular patterning.

What happens when Notch signaling is inhibited?

Inhibition of Notch signaling—through γ-secretase inhibitors, anti-Dll4 antibodies, or genetic deletion—produces a characteristic phenotype: excessive, disorganized angiogenesis with increased vessel branching and density. However, these vessels are non-functional: they are leaky, poorly perfused, and fail to establish proper arterial-venous identity. In tumors, Notch inhibition can paradoxically improve chemotherapy delivery by normalizing the abnormal vasculature, but chronic inhibition causes vascular neoplasms and gastrointestinal toxicity.

How is VEGF-Notch signaling studied experimentally?

Common approaches include: (1) genetic knockout or knockdown in mice and zebrafish (e.g., Dll4⁺/⁻ mice, fli1:EGFP zebrafish with dll4 morpholinos); (2) pharmacological inhibitors such as γ-secretase inhibitors (DAPT) or anti-Dll4 antibodies; (3) in vitro assays including Matrigel tube formation, spheroid sprouting, and co-culture with Notch reporter cells; and (4) biochemical analysis of pathway components (phosphorylated VEGFR2, NICD, HEY1/HEY2 expression).

Why is VEGF-Notch signaling important in cancer?

Tumors require new blood vessels to grow beyond a few millimeters in diameter. They secrete VEGF to stimulate angiogenesis, but the resulting vessels are often abnormal—tortuous, leaky, and poorly perfused. The VEGF-Notch balance determines the quality of the tumor vasculature. Anti-VEGF therapies (bevacizumab, aflibercept) are used clinically but often fail due to resistance. Notch inhibitors are being tested as an alternative strategy, either to normalize the vasculature or to disrupt the tumor's ability to form functional vessels.

What is the difference between tip and stalk cells?

Tip cells are the leading cells of a vascular sprout. They have high VEGF signaling, express high levels of Dll4, extend numerous filopodia, and are highly migratory but do not proliferate much. Stalk cells are the trailing cells. They have high Notch signaling (activated by Dll4 from the tip cell), low VEGFR2 expression, are less migratory, but proliferate to elongate the sprout and form the vascular lumen. The tip/stalk decision is dynamic and reversible—cells can switch between these states in response to changing VEGF and Notch signals.

Key Takeaways

VEGF and Notch signaling form an integrated feedback loop: VEGF induces Dll4, which activates Notch in neighboring cells to suppress VEGFR2, creating tip and stalk cell identities.
VEGFR2 is the primary signaling receptor for VEGF-A, activating MAPK/ERK, PI3K/AKT, and PLCγ/PKC pathways that drive endothelial proliferation, migration, and survival.
Notch signaling requires direct cell-cell contact and involves γ-secretase-mediated cleavage to release NICD, which activates HEY1/HEY2 transcriptional repressors.
Dll4 is the dominant vascular Notch ligand, and its gene dosage is critical for normal vessel patterning.
The tip/stalk cell decision is dynamic and reversible, not a fixed lineage commitment.
Dysregulation of the VEGF-Notch axis contributes to cancer, ocular neovascularization, and vascular malformations.
Anti-VEGF therapies are clinically established, while Notch inhibitors are in development but face challenges of toxicity and context-dependent effects.
The pathway is best understood as a spatial patterning system, not a simple linear cascade—context and cell-cell communication are everything.